Eftrenonacog alfa
Also known as: Alprolix, BeneFIX-Fc, INN: eftrenonacog alfa, recombinant factor IX Fc fusion protein, rFIX-Fc, rFIXFc
Source Eftrenonacog alfa at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Eftrenonacog alfa (Alprolix®) is a recombinant factor IX‑Fc fusion protein approved for prophylactic and on‑demand treatment of bleeding in patients with haemophilia B. By linking human FIX to the Fc domain of IgG1, the molecule achieves an extended circulating half‑life, allowing less frequent intravenous (and in some settings subcutaneous) infusions while maintaining haemostatic protection.
Mechanism of Action
The drug supplies functional factor IX, a key enzyme in the intrinsic coagulation cascade that activates factor X to generate thrombin. The Fc portion binds neonatal Fc receptors (FcRn) on endothelial cells, recycling the protein back into circulation and protecting it from lysosomal degradation. This Fc‑mediated recycling prolongs the plasma half‑life of FIX, resulting in sustained clotting activity after each dose.
What the Research Shows
Phase III multinational trials demonstrated that eftrenonacog alfa provides effective prophylaxis, peri‑operative management, and on‑demand bleed control across children, adolescents, and adults with severe haemophilia B, with low median annualised bleeding rates and reduced weekly factor consumption. Real‑world pharmacodynamic studies confirmed a mean trough FIX activity of about 4.6 IU/dL and a recovery of ~0.78 IU/dL per IU/kg, while thrombin‑generation assays highlighted velocity as the most sensitive haemostatic parameter. A 2024 indirect comparison suggested that an albumin‑fusion FIX product may achieve lower spontaneous bleed rates than eftrenonacog alfa, but no head‑to‑head trials exist. Laboratory monitoring is challenging: many routine clotting and chromogenic assays underestimate activity at low FIX levels, underscoring the need for assay selection.
Reported Benefits
Clinical data show that eftrenonacog alfa reduces bleeding frequency, permits dosing intervals longer than conventional FIX concentrates, and is effective in surgical settings. Patients report fewer infusions and sustained protection, and trials have not identified inhibitor development. The extended half‑life translates into lower factor consumption and improved quality of life for many users.
Limitations of the Evidence
Assay variability limits accurate monitoring, especially at low FIX concentrations, which can affect dose adjustments. Indirect comparisons hint that alternative extended‑half‑life products might offer superior control of spontaneous bleeds, but direct comparative evidence is lacking. Long‑term safety beyond five years remains under‑studied, and data on subcutaneous administration are minimal in the published literature.
Safety Considerations
Across trials and real‑world cohorts, eftrenonacog alfa was well tolerated; most adverse events were deemed unrelated to therapy and no inhibitors were reported. No major safety signals have emerged, but clinicians should be aware of potential assay‑related misinterpretation of FIX activity and monitor patients for typical infusion‑related reactions. Standard pharmacovigilance applies.
How It Is Administered
The product is supplied as a sterile solution for intravenous bolus injection; subcutaneous administration is listed in the product label but not detailed in the cited studies. Dosing is individualized based on body weight, bleed severity, and target FIX activity levels, with typical prophylactic schedules ranging from weekly to every 10–14 days.
Routes of Administration
Goals & Uses
- Hemophilia B prophylaxisPreventiveHigh
- Prophylaxis of bleeding in hemophilia BHematology / CoagulopathyHigh
- Extended dosing interval / reduced injection frequencyPatient Adherence / Quality Of LifeHigh
- Perioperative hemostasis managementSurgical / PerioperativeHigh
- Treatment of acute bleeding episodesHematology / CoagulopathyHigh
- On-demand treatment of bleeding episodesTherapeuticHigh
Contraindications
- Known inhibitors to factor IX with anaphylactic historyImmunologyHigh
- Known hypersensitivity to eftrenonacog alfa or any excipientAllergy / HypersensitivityHigh
- Life-threatening hypersensitivity to hamster proteinsAllergyHigh
- Presence of high-titer factor IX inhibitorsImmunogenicityModerate
- Known hypersensitivity to eftrenonacog alfa or any of its excipientsAllergyHigh
Adverse Effects
- Thrombotic eventsCardiovascularRare
- Hypersensitivity / anaphylaxisImmunologicalUncommon
- Injection site reactionsLocalCommon
- Injection site discomfortLocal / Infusion RelatedCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Development of inhibitory antibodies (inhibitors)ImmunologicRare
- Thromboembolic eventsCardiovascularRare
- ArthralgiaMusculoskeletalUncommonJoint pain
- Dysgeusia (altered taste)SensoryUncommon
Drug Interactions
- Anticoagulants (e.g., warfarin, direct oral anticoagulants)Moderate
- Activated prothrombin complex concentrates (aPCCs)High
- Recombinant FVIIa (eptacog alfa)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Neonates / infants under 6 monthsPediatricRelative
- Patients with pre-existing thrombotic risk factorsCardiovascularRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Pediatric patients <12 yearsAgeRelative
- Patients with known FIX inhibitorsImmunologicRelative
Regulatory Status
- European UnionApprovedApproved: Hemophilia B prophylaxis, On-demand treatment of bleeding episodesEMA approval in 2015.
- United StatesApprovedApproved: Hemophilia B prophylaxis, On-demand treatment of bleeding episodesFDA approval in 2016.
- United KingdomApprovedApproved: Hemophilia B prophylaxis, On-demand treatment of bleeding episodesMHRA approval aligned with EU status.
Approved by FDA (2016) and EMA (2015) for hemophilia B; marketed under the brand name Alprolix.
Evidence & Sources
- Journal ArticleModerateStroobants AK, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleLowAtsou S, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateLamb YN, Hoy SM2023-01-01T00:00:00.000000Z
- Journal ArticleModerateGuillet B, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateHoy SM2017-01-01T00:00:00.000000Z
- Journal ArticleModerateMiguelino MG, Powell JS2014-01-01T00:00:00.000000Z
Frequently Asked Questions
How does eftrenonacog alfa differ from standard factor IX concentrates?
It is a recombinant FIX linked to an IgG1 Fc fragment, which engages the neonatal Fc receptor to recycle the protein and extend its half‑life, allowing less frequent dosing while maintaining clotting activity.
Is eftrenonacog alfa safe for children with haemophilia B?
Clinical trials in previously treated children reported effective bleed control and a safety profile comparable to adults, with no inhibitors detected and adverse events generally unrelated to the drug.
Can routine laboratory tests reliably measure its activity?
Many routine one‑stage clotting and chromogenic assays underestimate activity at low FIX levels; selecting assays validated for extended‑half‑life products is essential for accurate monitoring.
What evidence exists for its use before surgery?
Phase III studies and real‑world reports show that peri‑operative administration of eftrenonacog alfa achieves adequate haemostasis for major surgeries across all age groups.
How does it compare to other extended‑half‑life FIX products?
An indirect comparison suggests that an albumin‑fusion FIX (rIX‑FP) may reduce spontaneous bleed rates more than eftrenonacog alfa, but no direct head‑to‑head trials have been conducted to confirm this.
What is Eftrenonacog alfa?
Eftrenonacog alfa (Alprolix®) is a recombinant factor IX‑Fc fusion protein approved for prophylactic and on‑demand treatment of bleeding in patients with haemophilia B. By linking human FIX to the Fc domain of IgG1, the molecule achieves an extended circulating half‑life, allowing less frequent intravenous (and in some settings subcutaneous) infusions while maintaining haemostatic protection.
What is Eftrenonacog alfa used for?
Eftrenonacog alfa is educationally associated with: Hemophilia B prophylaxis, Prophylaxis of bleeding in hemophilia B, Extended dosing interval / reduced injection frequency, Perioperative hemostasis management, Treatment of acute bleeding episodes, On-demand treatment of bleeding episodes. Educational only — not medical advice.
How is Eftrenonacog alfa administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Eftrenonacog alfa?
Reported adverse effects include: Thrombotic events, Hypersensitivity / anaphylaxis, Injection site reactions, Injection site discomfort, Headache, Development of inhibitory antibodies (inhibitors), Thromboembolic events, Arthralgia, Dysgeusia (altered taste). This list is not exhaustive — consult a qualified clinician.
Who should avoid Eftrenonacog alfa?
Recorded contraindications: Known inhibitors to factor IX with anaphylactic history, Known hypersensitivity to eftrenonacog alfa or any excipient, Life-threatening hypersensitivity to hamster proteins, Presence of high-titer factor IX inhibitors, Known hypersensitivity to eftrenonacog alfa or any of its excipients. Consult a qualified clinician before use.